Dear NVAX Executive Team: Once you start to come out with a barrage of great news, you need to consider 1:6 share split in order to slow down the constant SP manipulation by institutional shareholders and shorts.  Otherwise, we will keep witnessing the constant SP manipulations.
To Real Longs, please note that I gave examples of different SP levels. Regardless of which SP the management ends up issuing share split, the point is, it needs to be done at some time in the near future, and hopefully soon.
What a 1:6 share split would do for Novavax.  I used today's closing for the first example.
Novavax has 74mil shares in issue, while Moderna has 401mil shares in issue for a ratio of 5.4 Moderna shares for every Novavax share. Optics is a fact of life. It's not always rational nor logical, but it is very real. The optics here is that a Novavax share price of $180 “looks” expensive compared to a Moderna share price of $282, yes optics. The reality is that a $180 Novavax share price in comparative shares in issue numbers is only $30 relative to the Moderna share price. Again, optics, the excessive share price discount is patently obvious at $30. Novavax would do well to do a share split of 1:6 earlier rather than later to rebalance the shares in issue relationship for a more realistic reflection of the relative price relationship between Novavax and Moderna.
A six for one share split would take a $180 Novavax share price back to $30, and then, all naïve market and the not so naïve market participants would see how the Novavax share price is trading at a very attractive discount to competitors in the face of significant progress and competitive standing at this stage.
Let us suggest that the Novavax share price should be trading in the $400 to $450 range, Split the Novavax share six for one, and let us suggest that the share should be trading in the $67 to $70 range, and it sounds a lot more reasonable. Let's go one step further and suggest that the Novavax share price should be trading in the $540 to $600 range to be on par with the share price of Moderna in the pre-EUA application phase, and again, investors will balk at that suggestion but split the stock six for one, and a trading range of $90 to $100 is totally in line with where Moderna was trading prior to submitting EUA, and on top of it, Moderna did not have its Phase 3 trial data in hand at that stage.
Everybody has a risk profile, but the $30 Novavax share price vs. a $282 Moderna share price based on the same number of shares, the trading ranges of BioNTech and Moderna in the after Phase 3 trial data and pre EUA applications stage and given currently available information, certainly ranks with the best risk/reward opportunities in the market presently.$Novavax(NVAX)$